原发性视网膜色素变性 (retinitispigmentosa ,RP)是常见的单基因遗传性疾病 ,通常双眼发病 ,最终可导致患者失明。近几年 ,RP治疗的实验研究取得相当大的进展 ,基因治疗、生长因子治疗、视网膜移植和人工视网膜等都有所突破 ,后两者已用于人体试验。此外 ,对经典的药物疗法以及传统医学治疗方面也进行了新的探索。 Primary retinitis pigmentosa (RP) is a common single-gene hereditary disease, usually the onset of both eyes, eventually leading to blindness in patients. In recent years, considerable progress has been made in the experimental study of RP treatment. Gene therapy, growth factor therapy, retinal transplantation and artificial retina have all made breakthroughs. The latter two have been used in human trials. In addition, a new exploration has been made of classical medical therapies and traditional medical treatments.